Translational Medicine
Open Access
ISSN: 2161-1025
ISSN: 2161-1025
Dr. Min Li, MD
Executive Editor
Department of Cancer Research
University of Texas, Texas, USA
Dr. Min Li got his PhD from Emory University at Atlanta, Georgia in 2002. Under the supervision of Dr. Richard W. Compans, a world renowned virologist and immunologist, Dr. Li studied the regulation of a retrovirus envelope protein induced membrane fusion and the association with lipid rafts. He then moved on to Baylor College of Medicine at Houston, Texas, and started his career in cancer research as an Assistant Professor in 2004. Dr. Li joined the University of Texas Health Science Center at Houston, Medical School in 2010 as the Director of Cancer Research Program. His research interests include pancreatic cancer and brain tumor pathogenesis, translational research, new therapies and tumor vaccine development. Dr. Lis group is the first one to identify a zinc transporter (ZIP4) as a new molecular target in pancreatic cancer, and has developed a novel therapy to treat this malignancy.
Dr. Min Li got his PhD from Emory University at Atlanta, Georgia in 2002. Under the supervision of Dr. Richard W. Compans, a world renowned virologist and immunologist, Dr. Li studied the regulation of a retrovirus envelope protein induced membrane fusion and the association with lipid rafts. He then moved on to Baylor College of Medicine at Houston, Texas, and started his career in cancer research as an Assistant Professor in 2004. Dr. Li joined the University of Texas Health Science Center at Houston, Medical School in 2010 as the Director of Cancer Research Program. His research interests include pancreatic cancer and brain tumor pathogenesis, translational research, new therapies and tumor vaccine development. Dr. Lis group is the first one to identify a zinc transporter (ZIP4) as a new molecular target in pancreatic cancer, and has developed a novel therapy to treat this malignancy.